The Australian sickle cell disease market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Sickle cell disease is a group of inherited red blood cell disorders that affects hemoglobin, the protein that carries oxygen through the body. Normally, red blood cells are disc-shaped and flexible to move easily through the blood vessels. The blocked blood flow through the body can lead to serious problems, including stroke, eye problems, infections, and episodes of pain, called pain crises. Having sickle cell disease also raises your risk for severe illness from COVID-19. Sickle cell disease is a lifelong illness. A blood and bone marrow transplant is currently the only cure for sickle cell disease, but there are effective treatments that can reduce symptoms and prolong life. This enables as the fuelling factor for the Sickle cell disease in the forecasted period.
The sickle cell disease market is driven by the increasing prevalence of sickle cell disease. Besides, the availability of high unmet needs, increasing product pipeline for treating sickle cell anemia expected to create high demand for these treatment options. The sickle cell anemia treatment market is driven by increasing governments and regulatory bodies’ support using research and development investment, fast track approval for discovering newer treatments for this disorder. Better reimbursement policies and awareness of sickle cell diseases have affected the growth of the market.
Major Sickle Cell Diseases
Based on disease indication, the Australian sickle cell drugs market can be segmented into HbSS, HbSC, HbS beta-thalassemia, and sickle cell trait. HbSS and HbSβ0 are the most severe forms of SCD, while HbSC and HbSβ+ are generally milder diseases.